Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446784
Status:
COMPLETED
Last Update Posted:
2011-05-23
First Post:
2007-03-09
Brief Title:
Study Of The Safety Of CE 224545 And Methotrexate In Patients With Rheumatoid Arthritis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 1 Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CE 224535 is being developed for the treatment of rheumatoid arthritis The purpose of this study is to evaluate the safety and tolerability of CE 224535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None